AVCN-583601 is under clinical development by Avicanna and currently in Phase III for Epidermolysis Bullosa. According to GlobalData, Phase III drugs for Epidermolysis Bullosa does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the AVCN-583601 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AVCN-583601 overview
AVCN-583601 is under development for the treatment of epidermolysis bullosa. The drug candidate is a cannabinoid-based product and acts by targeting cannabinoid receptors CB1 and CB2. It is developed based on avicanna platform. It was administered through topical route.
See Also:
Avicanna overview
Avicanna is a company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products
For a complete picture of AVCN-583601’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
